Eli Lilly expanded its AI-driven drug discovery push by signing an agreement with Insilico Medicine to develop and commercialize preclinical oral therapeutics across multiple therapeutic areas. Under the deal, Lilly will pay $115 million upfront, with potential milestone payments totaling up to $2.75 billion based on development, regulatory and commercial achievements, plus tiered royalties on sales if any candidates are approved. Insilico will grant Lilly an exclusive global license for what the companies describe as potentially best-in-class, novel oral therapeutics in preclinical development; the announcement does not disclose the specific targets. The collaboration builds on a longer relationship between the two companies that began with Lilly licensing access to Insilico’s Pharma.AI software suite and later expanded into broader discovery cooperation. For Lilly, the deal reinforces an AI-focused BD strategy intended to feed a pipeline beyond near-term franchises and help address downstream revenue risk. For Insilico, the transaction provides substantial non-dilutive capital while leveraging Lilly’s development and commercialization capabilities to progress AI-discovered assets toward regulatory and market endpoints.